Prior to the COVID-19 pandemic, the relationship between ACE2, ACEIs, and SARS had been considered as possible evidence that ACE2 could serve as a therapeutic target [149], and the connection had been explored through in vitro and molecular docking analysis [150] but ultimately was not pursued clinically [151]. This evidence concerns the gene ACE2 and COVID-19.